# Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

> **NCT02924376** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 147 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT02924376
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-16
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-02-01
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02924376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02924376, "Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02924376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*